
AstraZeneca Pharma Share Price Rises 2.24% After Letter of Intent With Reliance's Strand Life Sciences
AstraZeneca Pharma share price Rs 6,168 on 17 Nov 2026, up 2.24%. LoI with Reliance unit Strand Life Sciences. Q2 FY27 PAT up 14.96% to Rs 62.33 cr. Down 29.76% YTD.
Updated: 18 Nov 2026 • 9:32 am
Posted by:

Quick Answer
The AstraZeneca Pharma share price rose 2.24% to Rs 6,168 on 17 November 2026 after AstraZeneca Pharma India signed a letter of intent with Strand Life Sciences, a Reliance subsidiary, to explore healthcare collaboration in India. The company said the arrangement is not a related-party transaction. The stock remains down 29.76% in 2026 and well below its 52-week high of Rs 9,469.50, even after Q2 FY27 profit rose 14.96% to Rs 62.33 crore.
The AstraZeneca Pharma share price closed 2.24% higher at Rs 6,168 on 17 November 2026 after the company announced a letter of intent with Strand Life Sciences, a subsidiary of Reliance. The news gave a lift to a stock that has had a difficult year, falling close to 30% since January.
Here is what the agreement covers, how the stock has performed, what the latest results show and the events investors should track.
Click Here – Get Free Investment Predictions
AstraZeneca Pharma Share Price: Key Numbers
Here is how the AstraZeneca Pharma share price has moved across time frames:
| Metric | Figure |
| Close on 17 Nov 2026 | Rs 6,168 (+2.24%) |
| One week | -5.36% |
| One month | +3.27% |
| Year to date | -29.76% |
| 52-week high | Rs 9,469.50 (18 Nov 2025) |
| Year low | Rs 5,640 (9 Oct 2026) |
| Market capitalisation | Rs 15,398.75 crore |
The Letter of Intent With Strand Life Sciences
AstraZeneca Pharma India signed a letter of intent on 17 November 2026 with Strand Life Sciences, a genomics and diagnostics company owned by Reliance, to explore collaboration in healthcare in India. In its exchange filing, the company said the arrangement is not a related-party transaction.
A letter of intent is a preliminary step that sets out the intention to work together; it is not a binding contract with defined financial terms. Investors should wait for any definitive agreement to understand the scope, revenue potential and obligations involved. Until then, the AstraZeneca Pharma share price is likely to trade more on results and approvals.
Track Pharma Stocks on the Univest Screener
Why a Genomics Partnership Could Matter
Strand Life Sciences works in genomic testing and diagnostics. AstraZeneca's portfolio in India includes a strong presence in oncology, where genetic testing increasingly guides which patients receive which therapies. Collaboration between a diagnostics provider and a drug company can help identify eligible patients earlier and widen access to targeted treatments.
Chaitanya Auti, Research Analyst at Univest, notes that the AstraZeneca Pharma share price reaction was measured, which fits the preliminary nature of the announcement. The market is likely to look for a definitive agreement and early commercial details before re-rating the stock on this news.
Q2 FY27 Results and DCGI Approval
- Profit after tax rose 14.96% to Rs 62.33 crore in Q2 FY27.
- Revenue rose 30.41% to Rs 729.1 crore.
- The Drug Controller General of India granted DCGI approval in November 2026 for Datverzo, a breast cancer therapy, expanding the company's oncology portfolio.
Revenue growth of over 30% shows strong demand for the company's products, though profit grew more slowly, suggesting higher costs during the quarter. These numbers frame the AstraZeneca Pharma share price more than the letter of intent does.
Corporate Event: Independent Director E-Voting
Shareholders are voting on the appointment of an independent director through e-voting, which runs from 18 November to 17 December 2026. Investors holding the stock can vote through their depository or the e-voting platform listed in the company's notice. The vote is a governance matter and is not expected to move the AstraZeneca Pharma share price by itself.
What Investors Should Watch
Four triggers could move the AstraZeneca Pharma share price in coming months:
- Whether the letter of intent turns into a definitive agreement, and its terms.
- Launch timeline and uptake of Datverzo in India.
- Margin trends in coming quarters after the gap between revenue and profit growth.
- The Rs 5,640 year low as the key support, and round-number zones such as Rs 6,500 above the current price.
Investors comparing pharma stocks can review sector peers such as Glenmark Pharmaceuticals on growth and valuation before making decisions.
Download the Univest iOS App or Univest Android App to get pharma sector research and stock analysis.
Final Word on AstraZeneca Pharma Share Price
The AstraZeneca Pharma share price gained 2.24% to Rs 6,168 on 17 November 2026 after a letter of intent with Reliance's Strand Life Sciences to explore healthcare collaboration. Q2 revenue grew over 30% and a new oncology approval adds to the pipeline, but the stock is still down nearly 30% this year. A definitive agreement and margin recovery are the next triggers to watch.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on AstraZeneca Pharma Share Price
Why did AstraZeneca Pharma share price rise on 17 November 2026?
Ans. AstraZeneca Pharma India shares rose 2.24% to Rs 6,168 on 17 November 2026 after the company signed a letter of intent with Strand Life Sciences, a Reliance subsidiary, to explore collaboration in healthcare in India. The company said the arrangement is not a related-party transaction. A letter of intent is preliminary and does not yet include binding financial terms.
What is Strand Life Sciences?
Ans. Strand Life Sciences is a genomics and diagnostics company owned by Reliance. It works in genetic testing and related healthcare services. A collaboration with AstraZeneca Pharma India could connect genetic testing with targeted therapies, particularly in areas such as oncology, where test results increasingly guide treatment decisions for patients.
What were AstraZeneca Pharma India's Q2 FY27 results?
Ans. For the second quarter of fiscal 2027, AstraZeneca Pharma India reported profit after tax of Rs 62.33 crore, up 14.96% from a year earlier, on revenue of Rs 729.1 crore, up 30.41%. Revenue grew faster than profit, indicating higher costs during the quarter. Investors will watch whether margins improve in the coming quarters.
How has AstraZeneca Pharma stock performed in 2026?
Ans. AstraZeneca Pharma India shares are down 29.76% year to date as of 17 November 2026, closing at Rs 6,168. The stock hit a 52-week high of Rs 9,469.50 on 18 November 2025 and a year low of Rs 5,640 on 9 October 2026. It gained 3.27% over the past month but fell 5.36% over the past week.
What is Datverzo?
Ans. Datverzo is a breast cancer therapy for which AstraZeneca Pharma India received approval from the Drug Controller General of India in November 2026. The approval expands the company's oncology portfolio in India. Its contribution to revenue will depend on launch timing, pricing, uptake by doctors and patients, and competition from other therapies.
When is the AstraZeneca Pharma e-voting for the independent director?
Ans. E-voting on the appointment of an independent director at AstraZeneca Pharma India runs from 18 November to 17 December 2026. Shareholders holding the stock on the cut-off date mentioned in the notice can vote through their depository participant or the e-voting platform specified by the company in its postal ballot notice.
Recent Articles

Capital Adequacy Ratio Explained: CRAR Formula, RBI Minimum Requirement, Tier 1 and Tier 2 Capital and How It Shows a Bank's Strength
18 November 2026

Earnings Yield vs Bond Yield Explained: Formula, the Yield Gap, How It Compares Stocks With G-Sec and What the Gap Can and Cannot Tell You
18 November 2026

CASA Ratio Explained: Formula, Why Banks Want a High CASA Share, How It Affects Margins and How to Compare Bank Stocks
18 November 2026

Gross NPA vs Net NPA Explained: Formulas, Provision Coverage Ratio, Slippages and How to Judge a Bank's Asset Quality
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Capital Adequacy Ratio Explained: CRAR Formula, RBI Minimum Requirement, Tier 1 and Tier 2 Capital and How It Shows a Bank's Strength
Earnings Yield vs Bond Yield Explained: Formula, the Yield Gap, How It Compares Stocks With G-Sec and What the Gap Can and Cannot Tell You
CASA Ratio Explained: Formula, Why Banks Want a High CASA Share, How It Affects Margins and How to Compare Bank Stocks
Gross NPA vs Net NPA Explained: Formulas, Provision Coverage Ratio, Slippages and How to Judge a Bank's Asset Quality
Net Interest Margin Explained: NIM Formula, What a Good NIM Is, Why It Changes and How to Compare Bank Stocks With It
Popular this week
Asian Paints Share Price Rises 2.02% as Softer Crude Eases Raw Material Worries for Paint Makers

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





